Disease · EFO_0007411

Orthomyxoviridae infectious disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Orthomyxoviridae infectious disease. Diseases, record EFO_0007411. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0007411

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Orthomyxoviridae infectious disease; Open Targets
Open Targets ID: EFO_0007411; Open Targets
Other names: Influenza with non-respiratory manifestation (disorder), Influenza with other manifestations, Influenza with other manifestations (disorder), Influenza with other manifestations NOS (disorder), Influenza, Human, Orthomyxoviridae Infections, Orthomyxoviridae disease, disease due to Orthomyxoviridae (disorder), flu, influenza, influenza infection, influenza virus infection, influenza with non-respiratory manifestation, orthomyxoviridae caused disease or disorder, orthomyxoviridae disease or disorder; Open Targets
Disease Ontology: DOID:4493; Disease Ontology
MeSH: D009976; MeSH
Highest stage of its drugs: Approval, for 22 of its 90 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs90

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OSELTAMIVIR	CHEMBL1229	Small molecule	Approval	EMA Human Drugs and TTD	60	56	56	Drugs and targets
INFLUENZA VIRUS VACCINE	CHEMBL2109042	Vaccine component	Approval	TTD	58	53	6	Drugs and targets
INFLUENZA A VIRUS, SPLIT VIRION	CHEMBL6068363	Vaccine component	Approval	TTD	52	47	0	Drugs and targets
BALOXAVIR MARBOXIL	CHEMBL4297503	Small molecule	Approval	DailyMed, EMA Human Drugs, FDA and TTD	17	13	13	Drugs and targets
ZANAMIVIR	CHEMBL222813	Small molecule	Approval	DailyMed, EMA Human Drugs and TTD	16	10	10	Drugs and targets
FAVIPIRAVIR	CHEMBL221722	Small molecule	Approval	PMDA and TTD	14	10	10	Drugs and targets
INGAVIRIN	CHEMBL4297291	Small molecule	Approval	TTD	8	7	7	Drugs and targets
OSELTAMIVIR PHOSPHATE	CHEMBL1200340	Small molecule	Approval	DailyMed	12	6	6	Drugs and targets
PERAMIVIR	CHEMBL3989402	Small molecule	Approval	DailyMed and TTD	7	4	4	Drugs and targets
ACETAMINOPHEN	CHEMBL112	Small molecule	Approval	DailyMed	5	2	2	Drugs and targets

1 to 10 of 90

See all 90 drugs

Targets56

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	8	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
PTGS1	Cyclooxygenase	4	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	4	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
GRIN1	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist	Approval	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist	Approval	https://conductscience.org/library/genes/2903	Drugs and targets
GRIN2B	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist	Approval	https://conductscience.org/library/genes/2904	Drugs and targets
GRIN2C	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist	Approval	https://conductscience.org/library/genes/2905	Drugs and targets
GRIN2D	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist	Approval	https://conductscience.org/library/genes/2906	Drugs and targets
GRIN3A	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist	Approval	https://conductscience.org/library/genes/116443	Drugs and targets
GRIN3B	Glutamate [NMDA] receptor	2	Glutamate [NMDA] receptor antagonist	Approval	https://conductscience.org/library/genes/116444	Drugs and targets

1 to 10 of 56

See all 56 targets

Trials136

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 48 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02949011	Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications	Phase 3	2,184	2019-11-06	Influenza	BALOXAVIR MARBOXIL, OSELTAMIVIR	Its record names the disease	ClinicalTrials.gov
NCT01199744	Relenza® Sentinel Site Monitoring Program in Japan		1,575	2011-04-12	Influenza, Human	ZANAMIVIR	Its record names the disease	ClinicalTrials.gov
NCT02954354	A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza	Phase 3	1,436	2018-12-14	Influenza	BALOXAVIR MARBOXIL	Its record names the disease	ClinicalTrials.gov
NCT03336619	A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza	Phase 3	1,030	2022-06-28	Influenza	NITAZOXANIDE	Its record names the disease	ClinicalTrials.gov
NCT00803595	A Multinational Phase III Study of CS-8958 (MARVEL)	Phase 3	1,002	2011-11-22	Influenza, Human	LANINAMIVIR OCTANOATE, OSELTAMIVIR	Its record names the disease	ClinicalTrials.gov
NCT01227967	Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications	Phase 2	881	2017-07-11	Influenza	AMANTADINE, OSELTAMIVIR, RIBAVIRIN	Its record names the disease	ClinicalTrials.gov
NCT00775450	Influenza Vaccine Revaccination in Ambulatory Elderly Subjects	Phase 2	807	2011-08-11	Influenza, Orthomyxovirus Infection, Myxovirus Infection	INFLUENZA VIRUS VACCINE	Its record names the disease	ClinicalTrials.gov
NCT01314911	Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults	Not applicable	716	2019-02-05	Influenza, Human	OSELTAMIVIR	Its record names the disease	ClinicalTrials.gov
NCT01231620	A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza	Phase 3	626	2017-11-20	Influenza, Human	OSELTAMIVIR, ZANAMIVIR	Its record names the disease	ClinicalTrials.gov
NCT01227421	Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza	Phase 2/3	624	2014-01-08	Influenza	NITAZOXANIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 136

See all 136 trials

Comparisons in its trials65

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Nitazoxanide vs Placebo: deaths from any cause	1 of 515	0 of 515	1,030	NCT03336619	Trial comparisons
Nitazoxanide vs Placebo: serious adverse events	2 of 515	1 of 515	1,030	NCT03336619	Trial comparisons
Combination Therapy vs Oseltamivir Monotherapy: 28-day Mortality	0 of 314	1 of 312	626	NCT01227967	Trial comparisons
Combination Therapy vs Oseltamivir Monotherapy: deaths from any cause	0 of 314	1 of 312	626	NCT01227967	Trial comparisons
Combination Therapy vs Oseltamivir Monotherapy: serious adverse events	14 of 314	6 of 312	626	NCT01227967	Trial comparisons
Nitazoxanide vs Placebo: Number of Subjects Experiencing One or More Complications of Influenza	50 of 314	45 of 306	620	NCT03336619	Trial comparisons
Oseltamivir vs Placebo: 28-day Mortality	0 of 277	0 of 279	556	NCT01314911	Trial comparisons
Oseltamivir vs Placebo: deaths from any cause	0 of 277	0 of 279	556	NCT01314911	Trial comparisons
Oseltamivir vs Placebo: serious adverse events	5 of 277	2 of 279	556	NCT01314911	Trial comparisons
Oseltamivir vs Placebo: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples	99 of 220	131 of 229	449	NCT01314911	Trial comparisons

1 to 10 of 65

See all 65 comparisons in its trials

Papers from its trials95

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40886716	RESULT	1	PubMed
40383127	RESULT	1	PubMed
38296965	RESULT	1	PubMed
37865101	RESULT	1	PubMed
37060915	RESULT	1	PubMed
35908569	RESULT	1	PubMed
35151397	RESULT	1	PubMed
34800427	RESULT	1	PubMed
34672950	RESULT	1	PubMed
34000257	RESULT	1	PubMed

1 to 10 of 95

See all 95 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0007411

GET https://conductscience.org/api/diseases/v1/EFO_0007411/drugs?page=2

API reference For AI assistants